Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $20.7 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 4757.04% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.7 million (up 4757.04% YoY) and the FY2025 annual result came in at $22.1 million, up 29.85% from the prior year.
• Other Accumulated Expenses was $20.7 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $22.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $22.1 million in Q4 2025 and bottomed at $329000.0 in Q1 2022.
• A 5-year average of $9.6 million and a median of $7.9 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses tumbled 96.27% — and 2026, when it jumped 4757.04%.
• Kiniksa Pharmaceuticals International's Other Accumulated Expenses stood at $5.8 million in 2022, then jumped by 37.21% to $7.9 million in 2023, then jumped by 115.91% to $17.0 million in 2024, then gained by 29.85% to $22.1 million in 2025, then decreased by 6.52% to $20.7 million in 2026.
• Business Quant data shows KNSA's Other Accumulated Expenses at $20.7 million in Q1 2026, $22.1 million in Q4 2025, and $20.5 million in Q3 2025.